Immuneering Corp (IMRX)
1.47
-0.07
(-4.55%)
USD |
NASDAQ |
May 17, 16:00
1.47
0.00 (0.00%)
After-Hours: 20:00
Immuneering Research and Development Expense (Annual): 41.62M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 41.62M |
| December 31, 2022 | 36.27M |
| December 31, 2021 | 26.54M |
| Date | Value |
|---|---|
| December 31, 2020 | 15.00M |
| December 31, 2019 | 4.279M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.279M
Minimum
2019
41.62M
Maximum
2023
24.74M
Average
26.54M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Geron Corp | 125.05M |
| SELLAS Life Sciences Group Inc | 24.01M |
| Elicio Therapeutics Inc | 23.85M |
| ADMA Biologics Inc | 3.30M |
| Outlook Therapeutics Inc | 26.45M |